Cyclacel pharmaceuticals reviews 2022 achievements and announces key business objectives for 2023

– determination of recommended phase 2 dose and start of phase 2 in 1q 2023 for oral fadraciclib –

CYCC Ratings Summary

CYCC Quant Ranking